Neuroanatomic specificity and time course of alterations in rat brain serotonergic pathways induced by MDMA (3,4‐methylenedioxymethamphetamine): Assessment using quantitative autoradiography
George Battaglia, John Sharkey, Michael J. Kuhar, Errol B. de Souza
Synapse August 1, 1991 DOI: 10.1002/syn.890080403 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Experimental study Peer reviewed |
|---|---|
| Population | Rats |
| Intervention | MDMA (3 |
| Dose | 20 mg/kg, b.i.d. for 4 days |
| Duration | 4-day treatment regimen; assessments at 18 hours and 2 weeks post-treatment |
| Topics | MDMA Serotonin |
| Keywords | Pharmacology |
| Citations | 113 |
| Key findings | MDMA causes selective, long-lasting degeneration of serotonin nerve terminals in many brain regions, while sparing serotonin cell bodies and catecholamine neurons, with region-specific differences in recovery over two weeks. |
Abstract
Abstract The Widely abused “designer” durg MDMA (3,4‐methylenedioxymethamphetamine) has been shown to caused marked and long‐lasting changes in brain serotonergic systems. The present study uses quantitative in vitro autoradiography of 3 H‐paroxetine labeled 5‐HT uptake sites to assess the time‐dependent effects of MDMA on 5‐HT neurons in specific neuroanatomic loci. Following treatment with MDMA (20 mg/kg, b.i.d. for 4 days), marked decreases in 5‐HT uptake sites were observed in a number of brain regions known to receive projections of ‐5HT neurons. These regions included cerebral cortex, caudate nucleus, hippocampus, nucleus accumbens, olfactory tubercle, superior and inferior colliculi, geniculate nuclei, and most thalamic nuclei. In contrast, other areas such as the septal nuclei and some thalamic nuclei which also receive 5‐HT projections were not substantially affected by this drug. In most regions, decreases in 5‐HT uptake sites occurred within 24 hours of the last dose of MDMA and persisted at the 2 week time point. Some regions such as dorsal striatum exhibited a time‐dependent reduction with greater reductions occurring at 2 weeks rather than immediately following the MDMA treatment regimen. The density of 5‐HT uptake sites in other regions such as endopiriform nucleus and substantia nigra at the 2 week versus 18 hour time point indicated some degree of region‐specific recovery. Regions which demonstrated no significant reduction in 5‐HT uptake sites included the dorsal and median raphe nuclei, ventral tegmental area, central grey, interpeduncluar nucleus, locus coerulus, pontine reticular formation and cerebellum. Likewise, region containing 5‐HT axons of passage (e.g., indusium griseum and lateral hypothalamus) appeared to be insensitive to the neurotoxic effects of MDMA on 5‐HT neurons. Furthermore, the neurotoxic effects of MDMA showed specificity in that the catecholamine neurons labeled by 3 H‐mazindol were unaffected by the treatment regimen. These data indicate that the preferential degeneration of serotonergic neurons by MDMA is mediated primarily at 5‐HT terminal regions, whereas regions containg 5‐HT perikarya and axons of passage remain relatively unaffected. In addition, the observed time‐dependent reductions and recovery of 5‐HT uptake sites which were detected within 2 weeks of the treatment regimen in certain brain regions suggest region‐specific differences in recovery of 5‐HT systems from MDMA‐induced lesion.
Comparable studies
Other preclinical and animal studies on MDMA, most cited first.
Citations in the library
Cited by 44
- The content of ecstasy tablets: implications for the study of their long‐term effects Addiction December 1, 2002
- In vivo detection of short- and long-term MDMA neurotoxicity?a positron emission tomography study in the living baboon brain Synapse June 1, 1998
- Potentiation of 3,4-methylenedioxymethamphetamine-induced dopamine release and serotonin neurotoxicity by 5-HT2 receptor agonists. European Journal of Pharmacology November 3, 1994
- 3,4-Methylenedioxymethamphetamine (Ecstasy)-Induced Learning and Memory Impairments Depend on the Age of Exposure during Early Development Journal of Neuroscience May 1, 2001
- In Vivo Imaging of Cerebral Serotonin Transporter and Serotonin2A Receptor Binding in 3,4-Methylenedioxymethamphetamine (MDMA or “Ecstasy”) and Hallucinogen Users Archives of General Psychiatry June 6, 2011
and 39 more in the library
Cites 7
- Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: immunocytochemical evidence for neurotoxicity Journal of Neuroscience August 1, 1988
- 3,4-Methylenedioxymethamphetamine and 3,4-methylenedioxyamphetamine destroy serotonin terminals in rat brain: quantification of neurodegeneration by measurement of [3H]paroxetine-labeled serotonin uptake sites. Journal of Pharmacology and Experimental Therapeutics September 1, 1987
- Hallucinogenic Amphetamine Selectively Destroys Brain Serotonin Nerve Terminals Science September 6, 1985
- (±3,4-Methylenedioxymethamphetamine Selectively Damages Central Serotonergic Neurons in Nonhuman Primates JAMA July 1, 1988
- 3,4-Methylenedioxymethamphetamine ("ecstasy") selectively destroys brain serotonin terminals in rhesus monkeys. Journal of Pharmacology and Experimental Therapeutics June 1, 1989
and 2 more in the library